Print

Purpose

The overall goal of this study is to investigate the added benefit of a neuromodulation intervention in individuals taking medication for treatment for Opioid Use Disorder(OUD).

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Ability to provide consent and comply with study procedures - Diagnostic and Statistical Manual of Mental Disorders criteria for OUD - Undergoing medication treatment for OUD. Participants may have current comorbid drug use, but primary diagnosis must be OUD - Intention to remain in the study until intervention completion.

Exclusion Criteria

  • Any medical condition with neurological sequelae - Head injury resulting in skull fracture or loss of consciousness of >30 minutes - Any tDCS or MRI contraindication (tDCS: history of seizures, metallic cranial plates/screws or implanted device, history of eczema on scalp. MRI: unapproved metallic implants, pacemakers or any other implanted electrical device, shrapnel, metallic braces, non-removable body piercings, pregnancy, breathing or movement disorder, or claustrophobia) - Any psychotic disorder (participants with other treated and stable psychiatric disorders will be included) - Presence of a condition that would render study measures impossible to administer or interpret - Age younger than 18 - Primary current substance use disorder on a substance other than opioids except for caffeine or nicotine - In treatment instead of jail - Pregnancy - Disrespectful behavior towards the investigators and staff.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
tDCS 		All intervention sessions will use the Soterix Mini-CT Remote tDCS device
  • Device: Transcranial Direct Current Stimulation (tDCS)
    We will deliver 2-mA tDCS current intensity during a 30 minute stimulation period (including a 30-second ramp-up and 30-second ramp-down period) to the dorsolateral prefrontal cortex. Electrodes will be fixed on marked locations based on the 10-20 EEG system. Anodal stimulating electrode will be over the left DLPFC (F3) and cathodal electrode over the right DLPFC (F4).

Recruiting Locations

University of Minnesota
Minneapolis, Minnesota 55455
Contact:
Calvin Cahill
952-444-0137
cahil138@umn.edu

More Details

Status
Recruiting
Sponsor
University of Minnesota

Study Contact

Calvin Cahill
952-444-0137
cahil138@umn.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.